Monitor Corporation (CEO Lee Kyung-jun), a company specializing in AI medical imaging diagnostic solutions, announced on the 1st that it has signed a joint marketing agreement with GE Healthcare to expand the breast imaging diagnostic market.
GE Healthcare recently strengthened its product competitiveness with the launch of its latest premium model, Invenia™ ABUS Premium*. Monitor Corporation's AI solution, MONCAD ABS DX (MONCAD), has demonstrated high lesion detection performance in ABUS images and received Class 3 approval from the Ministry of Food and Drug Safety for its M-Score, a quantitative breast cancer malignancy prediction function.
The two companies plan to pursue joint marketing activities, joint participation in academic conferences and exhibitions, and product promotion collaboration. Specifically, they aim to accelerate the spread of the early breast cancer detection solution by strengthening collaboration in Asian markets, such as Korea and Singapore, where commercialization is already underway.
“Our collaboration with GE Healthcare is a significant step forward in accelerating the global clinical expansion of AI-based diagnostic solutions,” said Lee Kyung-jun, CEO of Monitor Corporation. “Through the combination of ABUS and MONCAD, we will increase accessibility to early breast cancer diagnosis and provide a more accurate diagnostic environment.”
- See more related articles
You must be logged in to post a comment.